Myocardial bridge in a patient with castration-resistant metastatic prostate cancer treated with enzalutamide.
Giulia GiordanoLuca MastrantoniGiuseppe Ferdinando CollocaPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
Due to the high prevalence of prostate cancer in elderly patients at high cardiovascular risk and the increasing use of androgen receptor-targeted agent, a multidisciplinary approach is highly recommended to weigh survival benefits on toxicities. This case report may support the use of androgen receptor-targeted agent in elderly patients with controlled cardiovascular diseases, a population that is often excluded from randomised trials.
Keyphrases
- prostate cancer
- case report
- radical prostatectomy
- middle aged
- cardiovascular disease
- cancer therapy
- clinical trial
- community dwelling
- small cell lung cancer
- squamous cell carcinoma
- open label
- left ventricular
- study protocol
- double blind
- randomized controlled trial
- metabolic syndrome
- coronary artery disease
- atrial fibrillation
- newly diagnosed
- cardiovascular events